bleeding. cohen says these types of side effects were mostly mild in the trial. we do know that this has a low ratde of causing macro hemorrhage, a low rate less than 1%. in the phase 3 clinical trial there were seven deaths in the placebo group and six in the drug group. according to investigators though, none of the drugs were said to be due to the drug or aria. the new england journal of i had medicine published an additional death of a patient who had been given blood thinners. it s difficult to say it was the drug when another drug can cause significant bleeding. reporter: they agree while this drug shows promise, it must come with caution. for example, avoiding blood thinners while taking the medication. i will prescribe this drug in
reporter: dr. sharon cohen has been studying alzheimer s drugs for 30 years and was part of the clinical trials for lecanemab. what she is talking about is amyloid originating abnormality. it can look like this or this. it s brain swelling or brain bleeding. know cohen says these types of side effects were mostly mild in the trial. we do know that lecanemab has a low rate of causing macro hemorrhage, not necessarily fatal, but a low rate, less than 1%. reporter: in the phase three clinical trial, there were seven deaths in the placebo group and six deaths in the lecanemab group. according to the investigators, though, none of the deaths were considered to be due to lecanemab or a.r.e.a. the new england journal of medicine recently published details of an additional death of ooh patient on the drug who had been given blood thinners, raising additional concerns. it s pretty hard to say lecanemab caused that when we re
27%. what does that mean? according to models by the drug maker, someone who is 8le 0, like jack, could experience a two to three-year delay in progression to worsening his alzheimer s disease. we ve been targeting alzheimer s disease at the end stage when people have dementia when they can no longer take care of themselves and pathology and bplagues have built up and there s not much we can do. reporter: but nothing comes without risks. the ones that come with this drug have raised red flags. we have known that with almost all of the drugs in this class there can be a side effect of area. reporter: dr. sharon cohen has been studying alzheimer s drugs for 30 years and was part of the clinical trial. what she is talking about, area, is amaloyd related imaging related abnormality. it s brain swelling or brain